Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

pembrolizumab 2Cyclophosphamide 2siltuximab 1ruxolitinib 1ricolinostat 1repotrectinib 1pralsetinib 1ponatinib 1pomalidomide 1pamiparib 1fludarabine 1ficlatuzumab 1enzalutamide 1blinatumomab 1Taxes 1Radiation 1Pemetrexed 1Paclitaxel 1Gefitinib 1Drug Therapy 1Dexamethasone 1Cisplatin 1CPI-0610 1Bortezomib 1Biopsy 1Bevacizumab 1Bendamustine Hydrochloride 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms by Histologic Type × ricolinostat × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡